PCSK9 inhibitors for COVID-19: an opportunity to enhance the antiviral action of interferon in patients with hypercholesterolaemia.

A beneficial role for an efficient lowering of plasma cholesterol level in hypercholesterolemic patients with COVID-19, and especially in those with severe hypercholesterolemia since birth, i.e., patients with familial hypercholesterolemia (FH), has been suggested recently [1, 2]. FH patients suffer from endothelial dysfunction caused by a highly elevated serum low-density cholesterol (LDL-C) level which is often accompanied by an elevated level of lipoprotein (a) [Lp(a)] [3].